

Emanuela Onesti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9116078/publications.pdf>

Version: 2024-02-01

33
papers

1,535
citations

516710

16
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

1991
citing authors

#	ARTICLE	IF	CITATIONS
1	Nerve high-resolution ultrasonography in tangier disease. <i>Muscle and Nerve</i> , 2019, 59, 587-590.	2.2	2
2	Heteronymous H reflex in temporal muscle as sign of hyperexcitability in ALS patients. <i>Clinical Neurophysiology</i> , 2019, 130, 1455-1459.	1.5	6
3	Ecuzumab improves fatigue in refractory generalized myasthenia gravis. <i>Quality of Life Research</i> , 2019, 28, 2247-2254.	3.1	32
4	Neuromuscular magnetic stimulation counteracts muscle decline in ALS patients: results of a randomized, double-blind, controlled study. <i>Scientific Reports</i> , 2019, 9, 2837.	3.3	21
5	Long-term safety and efficacy of ecuzumab in generalized myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 60, 14-24.	2.2	162
6	Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2019, 18, 232-238.	1.4	11
7	Chronic inflammatory demyelinating polyneuropathy: evaluation of the vestibular system with cervical and ocular vestibular evoked myogenic potentials. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 1507-1512.	1.6	6
8	Repetitive transcranial magnetic stimulation for chronic neuropathic pain in patients with bladder pain syndrome/interstitial cystitis. <i>Neurourology and Urodynamics</i> , 2018, 37, 2678-2687.	1.5	34
9	Effects of visual deprivation on primary motor cortex excitability: a study on healthy subjects based on repetitive transcranial magnetic stimulation. <i>Experimental Brain Research</i> , 2017, 235, 2059-2067.	1.5	7
10	Safety and efficacy of ecuzumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	10.2	472
11	Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management. <i>Frontiers in Neurology</i> , 2017, 8, 94.	2.4	76
12	Acute Flaccid Paralysis by Enterovirus D68 Infection: First Italian Description in Adult Patient and Role of Electrophysiology. <i>Frontiers in Neurology</i> , 2017, 8, 638.	2.4	1
13	A Novel Mutation in ABCA1 Gene Causing Tangier Disease in an Italian Family with Uncommon Neurological Presentation. <i>Frontiers in Neurology</i> , 2016, 7, 185.	2.4	18
14	Laryngeal Sensitivity in Patients with Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2016, 7, 212.	2.4	22
15	Primary Progressive Orofacial Apraxia: A Ten-Year Long Follow-Up Case Report. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1039-1045.	2.6	1
16	Foot drop of central origin: a misleading alteration of nerve conduction study. <i>Neurological Sciences</i> , 2016, 37, 811-813.	1.9	4
17	Glutamate-Mediated Blood-Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery. <i>Journal of Neuroscience</i> , 2016, 36, 7727-7739.	3.6	129
18	Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3060-3065.	7.1	53

#	ARTICLE	IF	CITATIONS
19	Transcranial magnetic stimulation as a new tool to control pain perception. <i>World Journal of Anesthesiology</i> , 2016, 5, 15.	0.5	1
20	Communication of diagnosis in amyotrophic lateral sclerosis: stratification of patients for the estimation of the individual needs. <i>Frontiers in Psychology</i> , 2015, 6, 745.	2.1	4
21	Afferent Nerve Ending Density in the Human Laryngeal Mucosa: Potential Implications on Endoscopic Evaluation of Laryngeal Sensitivity. <i>Dysphagia</i> , 2015, 30, 139-144.	1.8	9
22	Cutaneous silent period recordings in demyelinating and axonal polyneuropathies. <i>Clinical Neurophysiology</i> , 2015, 126, 1780-1789.	1.5	15
23	Altered Cortical Synaptic Plasticity in Response to 5-Hz Repetitive Transcranial Magnetic Stimulation as a New Electrophysiological Finding in Amnesic Mild Cognitive Impairment Converting to Alzheimer's Disease: Results from a 4-year Prospective Cohort Study. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 253.	3.4	25
24	Partial Block by Riluzole of Muscle Sodium Channels in Myotubes from Amyotrophic Lateral Sclerosis Patients. <i>Neurology Research International</i> , 2014, 2014, 1-7.	1.3	9
25	A possible case of Hashimoto's encephalopathy after surgery and radiometabolic therapy for thyroid carcinoma. <i>Neurological Sciences</i> , 2013, 34, 1489-1491.	1.9	3
26	Leptomeningeal carcinomatosis in aggressive germ non-seminoma testicular tumor: A case report and review of literature. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1081-1085.	1.4	3
27	The importance of physician-patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability. <i>Neurological Sciences</i> , 2012, 33, 575-584.	1.9	37
28	Fatal herpetic encephalitis during brain radiotherapy in a cerebral metastasized breast cancer patient. <i>Journal of Neuro-Oncology</i> , 2010, 100, 137-140.	2.9	12
29	Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. <i>European Journal of Pain</i> , 2009, 13, 472-477.	2.8	44
30	Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis. <i>Clinical Neuropharmacology</i> , 2009, 32, 41-47.	0.7	87
31	Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. <i>Journal of the Neurological Sciences</i> , 2004, 218, 103-108.	0.6	146
32	Monthly corticosteroids decrease neutralizing antibodies to IFN- β : a randomized trial in multiple sclerosis. <i>Journal of Neurology</i> , 2002, 249, 50-56.	3.6	83
33	Back home. , 0, , 230-239.		0